Skip to main content
. Author manuscript; available in PMC: 2014 Dec 2.
Published in final edited form as: Ann Clin Exp Hypertens. 2014 Jan 6;2(1):1007.

Figure 2. Effects of CGRP on the proliferative pathways activities, ERK1 and ERK2.

Figure 2

Upper: sample western blots for ERK1 (left) and ERK2 (right) total and phosphorylated form with the corresponding loading control GAPDH. Lower: Bar graphs depicted the effects of CGRP1-37 in the presence or absence of antagonists (CGRP8-37) or Akt activator- (IGF-1) or down-regulator (Ad.Akt(K179M)). (N= 6, * p<0.05).